• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis to present data on novel immunoassay at 2018 British Thoracic Society Winter Meeting
Share
News

ProAxsis to present data on novel immunoassay at 2018 British Thoracic Society Winter Meeting

November 26, 2018
-
Posted by David Ribeiro

The potential benefits of ProAxsis’ novel ProteaseTag® Active Proteinase 3 Immunoassay will be discussed at the Winter meeting of the British Thoracic Society, which takes place between December 5th-7th at the Queen Elizabeth II Conference Centre, in London. Details of the abstract accepted by the conference review committee are detailed below:

P111: Quantification of Active Proteinase 3 in Sputum Samples Using a Novel Activity-Based Immunoassay

Presenting author: Dr Timothy Ferguson

Session – Understanding complications of cystic fibrosis

Thursday 6th December

 

Dr David Ribeiro, CEO of ProAxsis, said: “The ProteaseTag® Active Proteinase 3 Immunoassay was recently registered with a European CE Mark, and ProAxsis are delighted to be sharing data on this exciting new addition to the company’s portfolio of immunoassays.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

November 26, 2018

Related News

Other posts that you should not miss.
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis

December 23, 2016
-
Posted by Webmaster

In a significant new study, a team at the University of Dundee has shown for the first time that sputum …

Read More
December 23, 2016
Posted by Webmaster
Announcements, News

ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19

December 10, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded a high impact …

Read More
December 10, 2020
Posted by David Ribeiro
News, ProteaseTag®

ProAxsis gains further support from Innovate UK

July 24, 2017
-
Posted by Webmaster

Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for …

Read More
July 24, 2017
Posted by Webmaster
← PREVIOUS POST
New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases
NEXT POST →
ProAxsis assays selected for inclusion in major new ERS-funded study
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis to present data on novel immunoassay at 2018 British Thoracic Society Winter Meeting - ProAxsis